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Abstract
Objective: To assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of
efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.
Methods: HIV-infected adults with CD4+ T cell count #200/mm3 received standard 6-month tuberculosis treatment and
antiretroviral therapy including a daily-dose of 600 mg of efavirenz, irrespective of their body weight. Mid-dose blood
samples were drawn both on tuberculosis treatment (week +2 and week +6 after antiretroviral therapy initiation, and week
22 of follow-up) and off tuberculosis treatment (week 50 of follow-up). Considered therapeutic range was 1,000 to 4,000 ng/
mL. Multivariate analysis was performed to evaluate the association between efavirenz concentration below 1,000 ng/mL
and virological failure. Linear regression was used to test the association between efavirenz exposure and CD4+ T cell gain.
Severe side effects potentially related to efavirenz were described and their association with efavirenz exposure was tested
by multivariate analysis.
Results: Efavirenz plasma concentrations were available in 540 patients. Median [interquartile range] efavirenz
concentrations were 2,674 ng/mL [1,690–4,533], 2,667 ng/mL [1,753–4,494] and 2,799 ng/mL [1,804–4,744] at week +2,
week +6, week 22, respectively, and 2,766 ng/mL [1,941–3,976] at week 50. Efavirenz concentrations were lower at week 50
(off rifampicin) compared to week 22 (on rifampicin) (p,0.001). Late attendance to study visit and low hemoglobinemia
were the only factors associated with an increased risk of efavirenz concentration below 1,000 ng/mL. Efavirenz
concentration below 1,000 ng/mL was not associated with treatment failure. Efavirenz concentration above 4,000 ng/mL
was associated with higher risk of central nervous system side effects (p,0.001) and of hepatotoxicity (p,0.001).
Conclusion: Body weight and tuberculosis treatment were not associated with low efavirenz concentrations or treatment
failure, supporting the 600 mg daily-dose of efavirenz in HIV-tuberculosis co-infected patients. High efavirenz
concentrations were related to a higher risk of central nervous system side effects and hepatotoxicity.
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Introduction
Efavirenz is a non-nucleoside reverse transcriptase inhibitor
(NNRTI) widely used in combination with nucleoside reverse
transcriptase inhibitors as first-line treatment of HIV-1 infection.
Concomitant administration of antiretroviral therapy (ART) and
rifampicin - a potent inducer of drug metabolizing enzymes - is
challenging due to drug-drug interactions [1]. Efavirenz-contain-
ing ART is the first-line treatment recommended by the World
Health Organization (WHO) in HIV-infected patients, especially
when treated concurrently with tuberculosis treatment including
rifampicin and isoniazid for 6 months and ethambutol and
pyrazinamide for the first 2-months [2]. However, the appropriate
dose of efavirenz during rifampicin-based tuberculosis treatment
remains debated [3,4]. Some guidelines recommend increasing
efavirenz dosing to 800 mg daily when patient body weight is
above 50 kg [5,6] or above 60 kg [7,8] while the WHO and U.S.
Centers for Disease Control and Prevention recommend main-
taining a 600 mg daily dose, irrespective of patient’s body weight
[9,10].
The CAMELIA (ANRS 1295-CIPRA KH001) randomized
clinical trial showed a 34% reduction of mortality in severely
immunocompromised HIV-infected adults treated for tuberculosis
when efavirenz-containing ART was initiated two weeks com-
pared to eight weeks after tuberculosis treatment onset [11]. Here,
we describe plasma concentrations of efavirenz over one year of
follow-up on and off tuberculosis treatment in 540 patients
included in the CAMELIA trial. We also investigated risk factors
associated with efavirenz concentrations below the therapeutic
range and we analyzed the association between efavirenz exposure
and efficacy and toxicity.
Materials and Methods
The protocol of the CAMELIA trial and the TREND statement
check list of this longitudinal pharmacological study are available
as supporting information; see CAMELIA Protocol S1 and
TREND Statement Checklist S1.
Ethical considerations
The CAMELIA trial was approved by the Cambodian National
Ethics Committee and by the Institutional Review Boards of the
Immune Disease Institute of Harvard Medical School and
Me´decins Sans Frontie`res. This trial was conducted in accordance
with the Declaration of Helsinki [12] and all patients signed the
informed consent form prior to inclusion. The CAMELIA trial is
registered with ClinicalTrials.gov, number NCT00226434.
Study population and treatments
Main characteristics of enrolled patients and trial design have
been described elsewhere [11]. Among the 661 ART-naı¨ve, HIV-
infected adults with CD4+ T cell count #200/mm3 and newly
diagnosed, smear-positive tuberculosis who were recruited in
CAMELIA and followed in five Cambodian hospitals from 2006
to 2010, we conducted a longitudinal pharmacological study in
some of them. Tuberculosis treatment consisted of a six-months
regimen containing rifampicin (8–10 mg/kg/day), isoniazid (4–
5 mg/kg/day), ethambutol (15–20 mg/kg/day) and pyrazinamide
(20–30 mg/kg/day) as fixed dose combination (FDC) for the first
two months, followed by rifampicin (8–10 mg/kg/day) and
isoniazid (4–5 mg/kg/day) as FDC for the next four months. In
the CAMELIA trial, patients were randomized to initiate ART
either two weeks (‘‘early-ART’’ group) or eight weeks (‘‘late-ART’’
group) after onset of tuberculosis treatment. ART consisted of
lamivudine (150 mg) and stavudine (30 mg) twice daily and
efavirenz 600 mg once daily in the evening, irrespective of
patients’ body weight.
Blood samples and efavirenz assay
To account for the differential timing of ART initiation in the
two study arms, blood samples for determination of plasma
efavirenz concentration were drawn two weeks (W+2) and six
weeks (W+6) after ART initiation for all patients, corresponding to
four and eight weeks after tuberculosis treatment onset in the
early-ART group, and 10 and 14 weeks after tuberculosis
treatment onset in the late-ART group. Follow-up blood samples
were also drawn at week 22 and week 50 after tuberculosis
treatment onset in both groups. At this latter time point, patients
received efavirenz without concomitant tuberculosis treatment
(Figure 1).
Blood samples were collected early in the morning on EDTA
tubes 1462 hours after efavirenz intake and reflected mid-dosing
plasma concentrations [13,14]. After centrifugation, plasma was
transferred and stored at 280uC until analysis. Efavirenz was
assayed in plasma samples at the University of Health Sciences in
Phnom Penh, Cambodia, using a validated high-performance
liquid chromatography method with UV detection at 248 nm
[15]. The lower limit of quantification was 50 ng/mL. All samples
with concentration below this limit were removed from analysis as
these patients were considered as not taking efavirenz. The
laboratory participated to blind external quality controls provided
by Asqualab (France). Within and between days variability of the
assay - estimated from quality control samples inserted in each
analytical run - were below 15%. The therapeutic range of
efavirenz was considered to be 1,000–4,000 ng/mL, as previously
reported [14].
Efficacy markers and adverse events recorded
Virological efficacy of ART was assessed at week 8 in patients
from the early arm and at week 26 and week 50 for all patients. It
was described as the proportion of patients with undetectable
plasma HIV RNA (,250 copies/mL). CD4+ T cell gain since
ART initiation at week 26 and week 50 was considered for
immunological reconstitution in all patients. Clinical or biological
adverse events were reported and graded by on-site investigators
using the Division of AIDS table for grading the severity of adults
and pediatric adverse events [16]. All events were coded using the
MedDRA thesausus. Events of interest for this study were selected
in the following categories from the package insert of Sustiva [17]:
central nervous system (CNS) manifestations, elevated liver
enzymes, cutaneous manifestations. They were analyzed until
week 58. The number of side effects was reported by type and
severity grade.
Statistical analysis
Efavirenz plasma concentrations on and off rifampicin-based
tuberculosis treatment were described as median and inter quartile
range [IQR] and were compared at two consecutive time-points
using paired Wilcoxon tests. Factors associated with efavirenz
concentration below 1,000 ng/mL were identified using a mixed
effect logistic regression to account for multiple measurements
within patients. The main exposure variables were concomitant
tuberculosis treatment and patients’ body weight at the time of
sampling.
We evaluated the association between plasma concentrations of
efavirenz and: i) virological efficacy, defined as a viral load ,250
copies/mL at week 8 (only considering patients from the early
arm), week 26 and week 50 of follow-up, using a logistic regression;
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ii) immunological efficacy, defined as the CD4+ T cell gain at week
26 and week 50 of follow-up, using linear regression models; and
iii) occurrence of adverse events before week 58 of follow-up using
a logistic regression. Only plasma concentrations of efavirenz prior
to the evaluation time were considered. The threshold in efavirenz
concentrations was 1,000 ng/mL for the association with virolog-
ical and immunological efficacy, and 4,000 ng/mL for the
association with occurrence of adverse events. Other factors
considered in all these analyses were the study site, CAMELIA
study arm, gender, age at enrolment, body mass index (BMI) and
body weight as recorded at ART initiation and sampling time,
tuberculosis location, occurrence of paradoxical tuberculosis-
associated immune reconstitution inflammatory syndrome (IRIS),
as well as biological factors measured at ART initiation (defined as
the closest measurement within the month preceding ART
initiation for CD4+ T cells count, HIV RNA concentration,
hemoglobin, transaminases) and/or at the sampling time (week
262 weeks, week 864 weeks, week 2264 weeks and week 5068
weeks).
In all analyses, factors associated with a p-value ,0.20 in
univariate analysis were entered in the multivariate model. Factors
independently associated with the outcome were then identified
using a stepwise backward procedure based on the Wald test.
Two-sided hypotheses and tests were adopted for all statistical
inferences, a p-value ,0.05 being considered statistically signifi-
cant. All statistical analyses were performed using STATA 11
software (Stata Corp., College Station, Texas, USA).
Results
Study population
Among the 661 patients enrolled in the CAMELIA trial, 540
were considered in this analysis. The remaining 121 patients were
not included for various reasons shown in Figure 2. Character-
istics of the patients at ART initiation are displayed in Table 1.
Patients were at an advanced AIDS stage with a median [IQR]
CD4+ T cell count of 25 cells/mm3 [12–60] and median [IQR]
BMI of 17.3 kg/m2 [15.8–19.1]; 167 patients (31%) had a body
weight $50 kg, including 27 (5%) patients weighing $60 kg. The
number of patients with body weight $50 kg increased during the
study, reaching 261 (58.1%) and 277 (68.7%) at week 22 and week
50, respectively. The number of patients with body weight $60 kg
also increased reaching 58 (12.9%) and 85 (21.1%) at week 22 and
week 50, respectively.
Plasma concentrations of efavirenz
A total of 1,759 efavirenz concentration measurements were
available. Of the 540 patients, 430 (80%) had at least three
efavirenz concentrations available and 401 (74.3%) had samples
on and off concomitant tuberculosis treatment. A total of 40% of
samples were drawn when the patients were taking rifampicin and
their body weight was $50 kg and 8% were drawn when body
weight was $60 kg.
In the presence of rifampicin-based tuberculosis treatment,
median [IQR] efavirenz concentrations were 2,674 ng/mL
[1,690–4,533], 2,667 ng/mL [1,753–4,494] and 2,799 ng/mL
[1,804–4,744] at W+2, W+6 and week 22, respectively. At week
50, six months after the end of tuberculosis treatment, efavirenz
concentration was 2,766 ng/mL [1,941–3,976] (Figure 3). Efa-
virenz concentration increased between W+2 and W+6 and
between W+6 and week 22, and decreased between week 22 and
week 50 (p,0.001 for all three tests)
The distribution of efavirenz plasma concentration per sampling
week is displayed in Figure 4. Efavirenz concentration was
persistently within the therapeutic range in 243 patients (45.0%).
At W+2, W+6 and week 22, while receiving rifampicin-based
Figure 1. Study design.
doi:10.1371/journal.pone.0090350.g001
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tuberculosis treatment, 44 (9.7%), 24 (5.3%) and 15 (3.3%)
patients had efavirenz concentrations below 1,000 ng/mL. Off
tuberculosis treatment at week 50, 12 (3.0%) patients had
efavirenz concentrations below 1,000 ng/mL. The proportion of
efavirenz concentrations below 1,000 ng/mL was not different on
and off rifampicin-based tuberculosis treatment when comparing
data collected at weeks 22 and 50 (p = 0.76). Nine (1.7%) patients
had all measured concentrations below 1,000 ng/mL with an
efavirenz concentration of 643 ng/mL [111–756], 829 ng/mL
[828–904], and 825 ng/mL [204–915] at W+2, W+6 and week
22, respectively. These nine patients did not have efavirenz
concentration available at week 50. Among them, two patients
died after two and three months of follow-up, respectively, two
received a non efavirenz-based regimen at week 50 and five did
not have a sample drawn at this time. A total of 89 patients
(16.3%) had all concentrations above 4,000 ng/mL: efavirenz
concentration was 8,740 ng/mL [6,328–10,871], 10,563 ng/mL
[7,068–15,106], and 11,465 ng/mL [7,639–17,748] at W+2, W+6
and week 22, respectively. In these 89 patients, there was a
significantly lower efavirenz concentration at week 50 (9,633 ng/
mL [5,690–13,240]) compared to the previous concentration at
week 22 (p,0.001) (Figure 5). In multivariate analysis, factors
independently associated with an increased risk of efavirenz
Figure 2. Study population.
doi:10.1371/journal.pone.0090350.g002
Table 1. Characteristics of the 540 patients at ART initiation.
Male gender
n (%) 351 (65)
Age, in years
Median (IQR) 35 (30–41)
Weight category, in n (%)
,50 kg 373 (69.1)
$50 kg 167 (30.9)
Weight, in kg
Median (IQR) all patients (n = 540) 45 (40–51)
Median (IQR) males (n = 351) 48 (44–53)
Median (IQR) females (n = 189) 39 (35–44)
Body mass index, in kg/m2
Median (IQR) all patients (n = 540) 17.3 (15.8–19.1)
Median (IQR) males (n = 351) 18.0 (16.4–19.5)
Median (IQR) females (n = 189) 16.2 (15.1–18.2)
CD4+ T cells, in cells/mm3
Median (IQR) 25 (12–60)
Viral load, in log10 copies/mL
Median (IQR) 5.60 (5.20–6.0)
Haemoglobin, in g/L
Median (IQR) all patients (n = 540) 101 (83–115)
Median (IQR) males (n = 351) 105 (87–120)
Median (IQR) females (n = 189) 91 (78–107)
AST, in n (%)
#1.25 ULN 249 (46.1)
1.25 to 2.50 ULN 214 (39.6)
2.50 to 5.00 ULN 55 (10.2)
.5.00 ULN 22 (4.1)
ALT, in n (%)
#1.25 ULN 487 (90.2)
1.25 to 2.50 ULN 35 (6.5)
2.50 to 5.00 ULN 15 (2.8)
.5.00 ULN 3 (0.5)
Tuberculosis location, in n (%)
Pulmonary 371 (68.7)
Extra-pulmonary 51 (9.4)
Pulmonary and extra-pulmonary 118 (21.9)
ART: Antiretroviral Treatment; IQR: interquartile range; AST: aspartate
aminotransferase; ALT: alanine aminotransferase.
doi:10.1371/journal.pone.0090350.t001
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concentrations below 1,000 ng/mL were hemoglobinemia
#94 g/L as compared to.120 g/L (p = 0.03) and late attendance
to the current protocol visit (p = 0.001). By contrast, being a
woman decreased risk of efavirenz concentrations below
1,000 ng/mL (Table 2). Indeed, median efavirenz concentrations
were higher in women compared to men at all time points (3026
versus 2468 ng/mL; 3040 versus 2441 ng/mL; 3196 versus
2665 ng/mL and 2886 versus 2737 ng/mL at W+2, W+6, weeks
22 and 50, respectively p,0.001). Notably, only 3.5% of samples
drawn in women were below 1,000 ng/mL compared to 6.4% in
men. Concomitant rifampicin and a body weight $50 kg at ART
initiation and at the time of blood sampling were not associated
with an increased risk of efavirenz concentration below 1,000
ng/mL.
Efficacy outcomes
At week 8 (for the 277 patients from the ‘‘early-ART’’ group
with available viral load), week 26 and week 50, 206 (74%), 455
(91%) and 458 (97%) patients had plasma HIV RNA concentra-
tion ,250 copies/mL, respectively. Patients with at least one
efavirenz concentration below 1,000 ng/mL prior to the virolog-
ical evaluation time did not present a lower risk of virological
success at these three time-points than the other patients (median
[95% confidence interval (CI)]: 0.80 [0.35–1.86], 0.31 [0.07–1.32]
and 1.37 [0.38–4.94] at weeks 8, 26 and 50, respectively).
Efavirenz concentrations measured in 27 and 58 patients weighing
$60 kg at W+6 and week 22 were all above 900 ng/mL and were
not associated with virological failure at week 26 (p = 1.00 and
0.89, respectively). The median [IQR] CD4+ T cells gain from
baseline was 110 (69–168) cells/mm3 and 165 (108–226) cells/
mm3 at W26 and W50, respectively. Similarly, having at least one
efavirenz concentrations below 1,000 ng/mL prior to the immu-
nological evaluation time was not associated with a lower CD4+ T
cells gain at week 26 or week 50 (p = 0.65 and p = 0.82,
respectively).
Tolerance
During the trial, 55 (10.2%) patients experienced 55 severe
(grade 3–4) adverse effects, including: 47 hepatotoxicity (85.5%);
five CNS events (9.1%) -including two depressions, two deliriums
and one insomnia-; three mucocutaneous events (5.4%). Overall,
23 CNS side effects of all grades were observed in 22 patients.
They included sleep disorders (57%), depression (17%), vertigo
(13%) and delirium (13%). One patient with severe depression
committed suicide at 40.5 weeks of follow up. Efavirenz
concentrations of this patient reached 13,462 ng/mL at W+6
and 25,780 ng/mL at W22.
The risk of experiencing a severe adverse effect was not
significantly increased in patients who had efavirenz concentra-
tions that was at least once above, or always above 4,000 ng/mL,
when compared to patients who never had concentrations above
4,000 ng/mL (p = 0.30). However, the risk of developing a CNS
side effect, irrespective of the severity, was significantly increased
in patients who had efavirenz concentrations at least once above
4,000 ng/mL or those with concentrations always above
4,000 ng/mL, compared to patients who never experienced
efavirenz concentrations above 4,000 ng/mL (p,0.001, OR
[95% CI]: 2.72 [2.05–3.62] and p,0.001, 2.84 [2.08–3.89],
respectively). The risk of developing hepatotoxicity of any grade
was higher in patients with concentrations always above 4,000 ng/
mL (p,0.001, OR [95% CI]: 1.52 [1.33 –1.74]). However, having
intermittent efavirenz concentrations above 4,000 ng/mL did not
increase the risk of hepatotoxicity and even decreased the risk
(p,0.001, OR [95% CI]: 0.63 [0.56–0.70]).
Figure 3. Efavirenz plasma concentrations at sampling time.
doi:10.1371/journal.pone.0090350.g003
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Discussion
Efavirenz plasma concentrations on and off rifampicin-contain-
ing tuberculosis treatment were documented in more than 500
Southeast Asian patients co-infected with HIV and tuberculosis
from Cambodia. Our results show that after administration of a
daily dose of 600 mg efavirenz, efavirenz concentrations were not
decreased when efavirenz was administered with concomitant
rifampicin-isoniazid containing tuberculosis treatment, irrespective
of patient’s body weight. A slight decrease in efavirenz concen-
trations was observed after tuberculosis treatment discontinuation
in patients with concentrations higher than 4,000 ng/mL.
Throughout the duration of the study, a total of 45% of patients
had an efavirenz concentration within the 1,000–4,000 ng/mL
therapeutic range. The few patients with efavirenz concentrations
below the therapeutic range were not at higher risk of virological
failure. Importantly, we were able to demonstrate that patients
with efavirenz concentrations above 4,000 ng/mL had higher risk
of CNS side effects and hepatotoxicity. This finding, in keeping
with Marzolini et al.[14], had not been rigorously documented
previously in resource-limited settings.
The efavirenz concentrations measured in a Cambodian
population after 600 mg daily efavirenz administration, are in
keeping with those reported in studies conducted mainly in
Figure 4. Distribution of efavirenz plasma concentrations according to the therapeutic range at each sampling time.
doi:10.1371/journal.pone.0090350.g004
Figure 5. Efavirenz concentrations at week 22 and week 50 in patients whose efavirenz concentrations .4,000 ng/mL.
doi:10.1371/journal.pone.0090350.g005
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Table 2. Univariate and multivariate analysis of risk factors associated with efavirenz plasma concentration below 1,000 ng/mL.
Number of
efavirenz
samples N
Efavirenz
,1,000 ng/ml
N (%)
Crude OR (95% CI)
Univariate analysis P
Adjusted OR (95% CI)
Multivariate analysis P
Gender 0.02 0.005
Male 1,163 74 (6.4) 1 1
Female 596 21 (3.5) 0.46 (0.24–0.89) 0.37 (0.18–0.73)
Receiving rifampicin 0.02
No 385 12 (3.1) 1
Yes 1,374 83 (6.0) 2.17 (1.11–4.21)
Tuberculosis location 0.08
Pulmonary 1,217 72 (5.9) 1
Extra-pulmonary 167 2 (1.2) 0.16 (0.03–0.80)
Pulmonary and extra-pulmonary 375 21 (5.6) 1.00 (0.51–1.98)
Weight at ART initiation 0.06
,50 kg 1,196 55 (4.6) 1
50–59 kg 470 37 (7.9) 1.98 (1.08–3.64)
$60 kg 93 3 (3.2) 0.68 (0.15–2.99)
Viral load at ART initiation, log10 copies/mL 0.07
#5 335 15 (4.5) 1
5–6 988 66 (6.7) 1.55 (0.73–3.33)
.6 436 14 (3.2) 0.67 (0.26–1.73)
Body mass index at sampling 0.09
#15 kg/m2 118 8 (6.8) 2.08 (0.76–5.71)
15–16 kg/m2 162 11 (6.8) 2.41 (1.01–2.41)
16–17 kg/m2 173 8 (4.6) 1.40 (0.53–3.55)
17–18.5 kg/m2 367 27 (7.4) 2.21 (1.17–4.19)
.18.5 kg/m2 939 41 (4.4) 1
Weight at sampling 0.04
,50 kg 936 51 (5.4) 1
50–59 kg 630 41 (6.5) 1.04 (0.60–1.80)
$60 kg 193 3 (1.5) 0.17 (0.04–0.70)
CD4+ T cells at sampling
#50 cells/mm3 531 37 (7.0) 4.41 (1.70–11.42) 0.02
51–100 cells/mm3 302 22 (7.3) 4.37 (1.60–11.95)
101–200 cells/mm3 514 23 (4.5) 2.10 (0.81–5.44)
201–350 cells/mm3 293 8 (2.7) 1
.350 cells/mm3 104 4 (3.8) 1.61 (0.38–7.84)
Missing 15 1 (6.7) 4.27 (0.31–6.84)
ALT at sampling 0.14
#1.25 ULN 1,334 82 (6.1) 1
.1.25 ULN 421 13 (3.1) 0.51 (0.26–1.00)
Missing 4 0(0) Non estimable
Haemoglobin at sampling ,0.001 0.03
#70 g/L 56 9 (16.1) 8.05 (2.70–23.99) 4.77 (1.51–15.07)
71–80 g/L 73 9 (12.3) 6.23 (2.18–17.83) 4.06 (1.36–12.10)
81–94 g/L 140 14 (10.0) 4.10 (1.75–9.64) 2.66 (1.08–6.58)
95–120 g/L 612 30 (4.9) 1.68 (0.90–3.15) 1.37 (0.72–2.64)
.120 g/L 870 32 (3.7) 1 1
Missing 8 1 (12.5) 7.92 (0.51–121.93) 7.69 (0.57–102.99)
Low efavirenz concentration at previous visit ,0.001 0.01
No 1,148 31 (2.7) 1 1
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Caucasian and African American or African patients or in smaller
cohorts of Thai patients [18,19]. Our data suggest that efavirenz
disposition could be similar in patients from Southeast Asian
countries as in patients from Sub-Saharan Africa or with African
ancestors. We found that 24.3 to 30.1% of the measured efavirenz
concentrations in plasma were above 4,000 ng/mL when patients
received 600 mg of efavirenz daily, in agreement with other
studies [20,21]. It has been demonstrated that CYP2B6 is the main
enzyme involved in efavirenz metabolism [22] and that patients
carrying the loss of function CYP2B6 516TT genotype had a 3.5-
fold increase in efavirenz exposure [18,23,24,25,26]. Given that
the frequency of the loss of function allele CYP2B6 516 T is 34% in
Cambodian population, higher than in Caucasian population, this
could at least in part explain the high concentrations of efavirenz
measured in our population [26,27].
A number of studies have been conducted to assess the effect of
rifampicin or rifampicin based tuberculosis treatment co-admin-
istration on efavirenz concentrations, which reported results
different from those reported here. Three studies with a small
number of volunteers or patients showed that plasma efavirenz
levels were decreased in the presence of rifampicin alone or
rifampicin-based tuberculosis treatment [27,28,29]. Other studies
concluded that co-administration of rifampicin-based tuberculosis
treatment did not decrease efavirenz concentrations [21,30],
which support our results. By contrast, recent studies demonstrat-
ed slightly increased efavirenz concentrations when co-adminis-
tered with rifampicin-based tuberculosis treatment, especially in
African or African-American patients [4,20]. Our results are in
agreement with these unexpected results and indicate that patients
with efavirenz concentrations persistently above 4,000 ng/mL had
a small decrease in efavirenz concentration at tuberculosis
treatment cessation. The mechanism of this phenomenon is
unclear. An inhibitory effect of isoniazid, which is always given in
combination with rifampicin throughout tuberculosis treatment,
has been suggested [4].
Our findings in a large patient study show no significant
reduction in efavirenz concentrations with rifampicin-based
tuberculosis treatment co-administration irrespective of body
weight, consistent with data from a recently published study
[20]. In addition, we observed a small proportion of patients with
plasma concentrations below 1,000 ng/mL in our Southeast Asian
population, in agreement with previous studies conducted in
patients from different ethnicities [20,21,25,30]. Thus, our findings
strongly suggest that efavirenz dosing should not be increased
when efavirenz-based ART is initiated in patients on standard
tuberculosis treatment, irrespective of patient’s body weight.
Of note, late attendance to protocol visits was associated with a
higher risk of efavirenz concentrations below 1,000 ng/mL and
may be due to drug shortage between planned and actual protocol
visits. However, sustained efavirenz concentrations above 600 ng/
mL have already been reported in association with its long half-life
(.24 hours) [31]. Furthermore, no significant association was
found between efavirenz concentrations below 1,000 ng/mL and
detectable viral load at week 8 (in patients included in the ‘‘early-
ART’’ arm), at week 26 while on tuberculosis treatment and at one
year of follow-up. Overall, virological suppression was achieved in
97% of patients at week 50. In various settings, excellent
virological efficacy was also observed with 600 mg efavirenz co-
administered daily with rifampicin, which again supports the lack
of potent drug-drug interaction between rifampicin-based stan-
dard tuberculosis treatment [32,33,34,35,36,37,38]. Our observa-
tion that women were at reduced risk of having lower efavirenz
concentrations is in keeping with Burger et al [39]. Higher
concentrations in women might be the consequence of lower
weight compared to men. Unexpectedly, low efavirenz concen-
trations were related to low hemoglobinemia. The exact meaning
of this finding is unclear. The majority of our patients had anaemia
with median hemoglobinemia below the normal range at
inclusion, which could be related to both HIV and nutritional
deficiency [40]. We speculate that such advanced disease
presentations could alter efavirenz absorption, which remains to
be demonstrated.
High efavirenz plasma concentrations were associated with an
increased occurrence of CNS side effects of all severity grades. It
has been previously reported that up to 50% of patients receiving
efavirenz - especially if they had a slow CYP2B6 metabolizer
genotype - were likely to experience CNS toxicity
[41,42,43,44,45]. In our study, we observed a lower occurrence
of CNS side effects than in those studies. No specific side effects
questionnaire was administered to patients and events were
collected on the basis of spontaneous information given by the
patient or clinician observation during follow-up visits. It is likely
that side effects were under-reported by these very advanced
immunocompromised patients. Another hypothesis for this lower
rate of CNS toxicity is a high tolerance for CNS side effects
[14,43,46,47] that were often of mild severity and decreased over
time, as previously reported [41,48].
Table 2. Cont.
Number of
efavirenz
samples N
Efavirenz
,1,000 ng/ml
N (%)
Crude OR (95% CI)
Univariate analysis P
Adjusted OR (95% CI)
Multivariate analysis P
Yes 71 13 (18.3) 2.59 (0.68–9.89) 2.04 (0.54–7.76)
No previous sample available 540 51 (9.4) 3.70 (2.28–6.00) 2.48 (1.38–4.45)
Attendance at the current visit 0.04 0.01
On time 1,727 90 (5.2) 1 1
Late 32 5 (15.6) 4.10 (1.10–15.23) 5.36 (1.40–20.44)
Previous IRIS 0.06
No 1,354 80 (5.9) 1
Yes 405 15 (3.7) 0.49 (0.23–1.03)
Percentiles are gender-specific. IRIS: paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.
Sampling times were: 2 weeks after ART initiation, 6 weeks after ART initiation, at 22 weeks of follow-up, and at 50 weeks of follow-up. See text for details.
doi:10.1371/journal.pone.0090350.t002
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Depending on the considered studies, efavirenz plasma
concentrations above 4,000 ng/mL were [14,43,46,47] or were
not [24,41,48,49] associated with efavirenz adverse events. In the
2NN study [50], no relationship was observed between CNS/
psychiatric events and efavirenz exposure, except in Thailand
(p,0.001, OR [95% CI] = 5.8 [2.5–3.6]). In this study efavirenz
concentration was associated with elevation of liver enzymes in
keeping with our data recorded in patients from Cambodia
(p = 0.021, OR [95% CI] = 4.41: [1.3–15.5]).
Our study presents some limitations. First, patients with a high
body weight were not present in our study population, as only 27
patients at W+6 and 58 patients at week 22 had a body weight of
60 kg or above. Indeed high body weight is not common in
Southeast Asia and in patients with such advanced disease
presentation. However, efavirenz concentrations were not associ-
ated with virological failure (observed in 8%) at week 26 in these
patients. Second, efavirenz pharmacokinetic characteristics were
not fully characterized in our population. Mid-dose and not pre-
dose trough concentrations were collected as a surrogate of
efavirenz exposure. However, such approximation is acceptable as
efavirenz has an elimination half-life longer than the 24 h-dosing
interval, which would minimize fluctuations between peak and
trough concentrations. In addition, the genetic polymorphism of
CYP2B6 G516T, which explained at least part of the large inter-
individual variability of efavirenz concentrations, was not charac-
terized in these 540 patients. Lastly, tolerance of efavirenz was not
assessed by systematic questionnaires leading to potential under
reporting of side effects. It could be argued that all effects reported
in our study were representative of tolerance in real life situation.
Although elevation of liver enzymes and hepatotoxicity were
related to high efavirenz concentrations, efavirenz may not be the
only associated factor. Tuberculosis treatment could favor
transient liver toxicity and our one year study did not allow long
term evaluation of efavirenz related hepatotoxicity. In addition,
hepatitis C status of included patients was not recorded in the
CAMELIA study. Our finding that CNS adverse effects were
related to high efavirenz concentrations should favor initiation of
clinical trials evaluating lower efavirenz dosing and the develop-
ment of pharmacovigilance to carefully record adverse events
occurrence in resource-limited countries.
In conclusion, our study provided efavirenz plasma concentra-
tions in a large cohort of Southeast Asian patients receiving a daily
standard-dose of 600 mg co-administered with rifampicin-based
tuberculosis treatment. We found that efavirenz concentrations
were in the same range than in other studies mostly conducted in
African HIV-tuberculosis co-infected patients, demonstrating that
rifampicin-based tuberculosis treatment does not impair efavirenz
exposure and efficacy, irrespective of body weight. A proportion of
patients with high efavirenz concentrations were at higher risk of
CNS side events occurrence. Whether efavirenz dosing should be
reduced in these patients to improve tolerance warrants further
study.
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